j
Meanwhile, Bristol-Myers Squibb achieved publicity success of the chimeric T-cell antigen receptor (CAR-T) in early 2021 with the approval of Breyanzi (smooth-cel), which last week obtained second-line approval for giant relapses. or refractory B-cell lymphoma (LBCL) through the U. S. Food and Drug Administration. U. S. (FDA) — and Abecma (ide-cel) for myeloma.
In March 2022, the FDA approved a CAR-T moment for Johnson-shaped myeloma.
These 3 CAR-T products come with changed lentiviruses. However, the source of lentiviral vectors (LVV) has been affected in recent years, as mobile and gene treatment lines, along with COVID-related desires, have driven demand.
“Lentivirus remains a restricting element for all mobile therapies,” said Jennifer Taubert, executive vice president of pharmaceuticals at J.
“What we’ve done is make an investment, whether it’s in the U. S. In the U. S. and outdoors, in giant capacity and giant services that will eventually get us off the critical path, so as we continue to launch Carvykti around the world, as I move it in the previous treatment, and hopefully even in the frontline parameters, this lentivirus won’t be any kind of thing that restricts the pace for us.
Among J’s investments
Speaking at the same conference, Adam Lenkowsky, senior vice president and general manager of U. S. marketing. A U. S. representative at Bristol-Myers Squibb also spoke about the need to protect the source of lentivirals given the growing demand for CAR-T.
“We are excited about what we are seeing with the call for publicity for CAR T, either Abecma or Breyanzi. Starting with BCMA in multiple myeloma, we talked about expanding our vector capacity, and we’re doing that now,” he said. “You will see that this will start to manifest itself in advertising sales until the end of the year. “
Bristol-Myers Squibb began the structure last year at a 244,000-square-foot mobile treatment facility in Devens, Massachusetts, and ad production is expected to begin through 2023. Bristol-Myers The company is also structuring a CAR-T facility at Leiden Bio Science Park in the Netherlands and has ongoing mobile treatment operations at sites in Bothell, Washington, and two sites in New Jersey (Summit and Warren).
Categories: BioProcess Insider, Facilities & Capacity, Global Markets